NCT01172223View on ClinicalTrials.gov

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

December 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Myocet (Non-pegylated liposomal doxorubicin (NPLD))

60 mg/m\^2 i.v. day 1 q3 weeks

DRUG

Paclitaxel

175 mg/m\^2 i.v. day 1 q3 weeks

DRUG

Lapatinib (GW572016, Tykerb)

750-1500 mg/d orally daily until the day of the definitive surgery

Trial Locations (1)

Unknown

Sana Klinikum Lichtenberg, Berlin

All Listed Sponsors
lead

Prof Dirk Elling

OTHER

NCT01172223 - Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer | Biotech Hunter | Biotech Hunter